Shareholder Alert Issued for Vistagen Therapeutics Investors

NEW YORK, Feb. 19, 2026 — A nationally recognized investor rights law firm, Bernstein Liebhard LLP, has issued an important reminder to shareholders of Vistagen Therapeutics, Inc., traded on the NASDAQ under the ticker symbol VTGN, regarding an upcoming legal deadline tied to a pending securities class action lawsuit. The notice urges eligible investors to review their potential rights and take action before the deadline arrives.

What This Alert Means

This shareholder alert serves as a formal reminder that the deadline for investors to participate in a securities class action lawsuit filed against Vistagen Therapeutics is approaching. The class action alleges that Vistagen may have made materially misleading statements or omissions concerning certain aspects of its business, which may have impacted investors financially.

The lawsuit was initiated on behalf of investors who acquired shares of the company’s common stock during a specific period of time, and who may have suffered losses as a result of stock price changes influenced by the alleged misrepresentations.

Deadline Reminder for Eligible Shareholders

Bernstein Liebhard LLP has reminded shareholders that there is a critical deadline to act in order to participate in this class action lawsuit. Investors who believe they are part of the eligible class must take steps before this deadline in order to be represented in the legal proceedings or to be considered for any potential recovery.

Although the exact deadline date is not repeated in this particular notice, past filings and related alerts from the law firm and other legal counsel indicate that the deadline for filing lead plaintiff motions is March 16, 2026.

About the Securities Class Action Lawsuit

The underlying lawsuit was brought on behalf of a group of shareholders who purchased or acquired Vistagen Therapeutics common stock within a defined class period. According to information from related legal announcements, this class period spans from April 1, 2024 to December 16, 2025, inclusive.

The complaint alleges that the company and, in some cases, its executives made false and/or misleading statements related to the company’s drug development efforts, particularly the progress and outlook of clinical trials for its investigational therapy candidates. Investors argue that these alleged statements lacked transparency and may have misled the market.

One drug repeatedly mentioned in shareholder alerts is fasedienol, a therapy candidate being studied in the Phase 3 PALISADE-3 clinical trial as a potential rapid-onset treatment for social anxiety disorder and other central nervous system conditions. Allegations include overstatements of the drug’s likely success, contributing to inflated stock prices that later declined once actual trial outcomes or disclosures became publicly known.

Who May Be Eligible?

Investors who fall into one or more of the following categories may be considered part of the class:

• Purchased or acquired Vistagen Therapeutics common stock between April 1, 2024 and December 16, 2025;
• Held or sold shares during that period;
• Suffered financial losses related to changes in the VTGN stock price that coincide with public disclosures during that class period.

Why This Lawsuit Matters

Securities class action lawsuits are a legal mechanism that allow investors to seek recovery when they believe a publicly-traded company has made false or misleading statements that affect investment value. If the court certifies the class and eventually finds in favor of the plaintiffs or reaches a settlement, class members may receive compensation.

A lead plaintiff plays a central role in such lawsuits by representing the interests of the entire class, overseeing litigation strategy, and helping work with attorneys to pursue recovery. Investors considering taking on this role must file formal documentation before the deadline.

Action Steps for Investors

If you believe you qualify as a member of the class, the following steps may be advisable:

1. Review all personal transaction records related to Vistagen Therapeutics stock purchases and sales during the class period;
2. Contact legal counsel familiar with securities class actions to discuss your rights and options;
3. Consider whether you wish to serve as lead plaintiff or simply maintain passive class membership;
4. Submit any required filings or documentation before the deadline.

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a law firm specializing in investor rights litigation, representing shareholders in class action lawsuits involving publicly traded companies. The firm has a long history of pursuing cases involving securities fraud, corporate misrepresentation, and other legal claims on behalf of investors.

According to the GlobeNewswire press release, the firm has been retained to remind investors of this particular case and the approaching deadline, and it provides contact information for shareholders seeking additional information.

Contact Details for Further Information

Investors interested in learning more about the case or discussing their legal rights may contact:

Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
Phone: (212) 951-2030
Email: [email protected]
Website: https://www.bernlieb.com

Conclusion

The reminder from Bernstein Liebhard LLP highlights a significant legal opportunity for shareholders of Vistagen Therapeutics, Inc. who may have been affected by alleged misstatements during the class period. With a critical filing deadline approaching, investors who believe they qualify are advised to take prompt action, consult legal counsel if necessary, and carefully review their rights and options in the securities class action lawsuit.

#VistagenTherapeutics #VTGN #ShareholderAlert #ClassActionDeadline #SlimScan #GrowthStocks #CANSLIM